Research programme: anti-VPAC antibody therapeutics - ThromboGenics

Alternative Names: Anti-VPAC1 antibody

Latest Information Update: 04 Nov 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator University of Leuven
Developer ThromboGenics
Class Monoclonal antibodies
Mechanism of Action Pituitary-adenylate-cyclase-activating-polypeptide-type I-receptor-antagonists; Vasoactive intestinal polypeptide antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Thrombocytopenia

Most Recent Events

04 Nov 2017 No recent reports of development identified for preclinical development in Thrombocytopenia in Europe (Parenteral)
14 Nov 2007 Thrombogenics has selected an anti-VPAC antibody candidate for the treatment of thrombocytopenia
22 May 2007 Preclinical trials in Thrombocytopenia in Europe (Parenteral)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.